Overexpression of c-Myb is associated with suppression of distant metastases in colorectal carcinoma
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
26873484
DOI
10.1007/s13277-016-4956-7
PII: 10.1007/s13277-016-4956-7
Knihovny.cz E-resources
- Keywords
- Colorectal cancer, Immunohistochemistry, Metastases, c-Myb, mRNA,
- MeSH
- Adenocarcinoma genetics secondary MeSH
- Cell Differentiation MeSH
- Adult MeSH
- Down-Regulation MeSH
- Genes, myb * MeSH
- Neoplasm Invasiveness MeSH
- Colorectal Neoplasms genetics pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphatic Metastasis MeSH
- RNA, Messenger biosynthesis MeSH
- Neoplasm Proteins biosynthesis genetics MeSH
- Proto-Oncogene Proteins c-myb biosynthesis genetics MeSH
- Gene Expression Regulation, Neoplastic MeSH
- RNA, Neoplasm biosynthesis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- RNA, Messenger MeSH
- Neoplasm Proteins MeSH
- Proto-Oncogene Proteins c-myb MeSH
- RNA, Neoplasm MeSH
The MYB gene codes for the c-Myb transcription factor maintaining proliferation of colon epithelial progenitors, thus controlling colon development and homeostasis. This gene is overexpressed in early phases of colorectal cancer (CRC) tumorigenesis. The aim of this study was to examine the expression of c-Myb in CRC tissue samples both at the messenger RNA (mRNA) and protein levels and to evaluate their associations with clinicopathological characteristics in a group of 108 CRC patients. Statistically significant negative association was found between the frequency of the c-Myb-positive tumor cells assessed by immunohistochemistry and the presence of distant metastases (p < 0.01) but not tumor differentiation, tumor stage, lymph node involvement, vascular invasion, tumor localization, age, and gender of the patients. Although the c-Myb protein level in the tumor tissue correlated with its mRNA level, no significant association between MYB mRNA and any clinicopathological characteristics was observed. We conclude that albeit overexpression of c-Myb is considered as an important factor contributing to early phases of CRC tumorigenesis, it may later have negative effect on tumor cell dissemination as observed recently in breast cancer as well. Further studies are required to explain the role of c-Myb during formation of CRC distant metastases.
1st Department of Surgery St Anne's University Hospital Brno Czech Republic
Department of Oncology St Anne's University Hospital Brno Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
See more in PubMed
Cell Cycle. 2011 Dec 1;10(23):4149-61 PubMed
Am J Hematol. 2012 Oct;87(10):969-76 PubMed
Genes Chromosomes Cancer. 2006 Dec;45(12):1143-54 PubMed
Oral Oncol. 2008 Apr;44(4):383-92 PubMed
Mol Cancer. 2012 Mar 23;11:15 PubMed
Carcinogenesis. 2012 Jun;33(6):1149-57 PubMed
Bone. 2015 Jul;76:97-106 PubMed
Anticancer Res. 1994 May-Jun;14(3B):1433-40 PubMed
Clin Transl Oncol. 2013 Oct;15(10):818-24 PubMed
Cell Growth Differ. 1992 Oct;3(10):723-30 PubMed
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 PubMed
Nat Rev Genet. 2012 Mar 13;13(4):227-32 PubMed
Cancer Res. 1998 Nov 15;58(22):5168-75 PubMed
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18740-4 PubMed
Cancer Lett. 2013 Nov 28;341(1):97-104 PubMed
Blood. 2007 Aug 15;110(4):1251-61 PubMed
Comput Math Methods Med. 2014;2014:813067 PubMed
J Biol Chem. 2010 Sep 17;285(38):29434-45 PubMed
Cancer Res. 2011 Nov 15;71(22):7029-37 PubMed
BMC Genomics. 2009 Aug 07;10:365 PubMed
Cell Death Differ. 2009 Nov;16(11):1530-8 PubMed
Cancer Res. 1987 Oct 15;47(20):5266-9 PubMed
Virchows Arch. 2014 Mar;464(3):379-91 PubMed
Cancer Res. 2000 Oct 1;60(19):5323-8 PubMed
Anticancer Res. 2001 Sep-Oct;21(5):3185-92 PubMed
BMC Mol Biol. 2010 Feb 01;11:12 PubMed
Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13762-7 PubMed
Circ Res. 2008 Mar 14;102(5):554-61 PubMed
FEBS Lett. 2009 Dec 17;583(24):3966-73 PubMed
J Exp Clin Cancer Res. 2010 Dec 30;29:172 PubMed
Mod Pathol. 2011 Sep;24(9):1169-76 PubMed
Genes Dev. 1996 Nov 1;10(21):2732-44 PubMed
Stem Cells. 2008 Jan;26(1):173-81 PubMed
J Gastroenterol Hepatol. 2012 Jan;27(1):39-50 PubMed
Stem Cells. 2011 Dec;29(12):2042-50 PubMed
Oncogene. 1999 Oct 14;18(42):5821-30 PubMed
Cancer Res. 1997 Aug 1;57(15):3135-9 PubMed
Am J Pathol. 2001 Apr;158(4):1289-99 PubMed
Oncogene. 1997 Apr 10;14(14):1715-23 PubMed
Cell Prolif. 2015 Feb;48(1):78-85 PubMed
Cell Cycle. 2010 Aug 1;9(15):2986-95 PubMed
Oncogene. 2016 May 12;35(19):2475-84 PubMed
Stem Cell Res. 2014 Nov;13(3 Pt A):355-66 PubMed
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7265-70 PubMed
Cancer Lett. 1990 Jun 30;52(1):57-62 PubMed
Cancers (Basel). 2014 Oct 02;6(4):2049-71 PubMed
Anticancer Res. 1998 Mar-Apr;18(2A):1129-35 PubMed
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3829-34 PubMed
Transcription factor c-Myb: novel prognostic factor in osteosarcoma
c-Myb interferes with inflammatory IL1α-NF-κB pathway in breast cancer cells
Low infiltration of tumor-associated macrophages in high c-Myb-expressing breast tumors
High c-Myb Expression Associates with Good Prognosis in Colorectal Carcinoma
